Iowa hospital implements Pharmacy OneSource’s pharmacy software
Bellevue, Wash. A company that makes software for more than 1,300 hospitals in the United States announced Tuesday that a hospital in Cedar Rapids, Iowa, selected its software to establish benchmarks and trending of clinical and quality pharmacy activities.
Pharmacy OneSource said the Mercy Medical Center has implemented its Quantifi software.
“Quantifi has given Mercy Medical Center an accurate and consistent manner in which to report and track pharmacist interventions,” Mercy Medical Center director of pharmacy Desmond Waters said in a statement. “It also gives our pharmacy robust reporting in order to make real-time, informative patient care decisions.”
Quantifi allows pharmacists to document their clinical interventions, adverse events and adverse drug reactions quickly over the Internet or on handheld computers through a series of menus, drop lists and input screens.
Teva Pharmaceuticals and Lonza Group join to market biosimilars
Jerusalem As the possibility of a bill to allow Food and Drug Administration approval of biosimilars looms in Congress, two companies are already taking the initiative.
Teva Pharmaceutical Industries announced Tuesday a partnership with Lonza Group to establish a joint venture to develop, manufacture and market biosimilars. The two companies did not specify where they would market the drugs.”We had identified biosimilars as a major growth driver for Teva in our long-term strategy and have been augmenting our knowledge base, capabilities and infrastructure to position Teva as a leader in this market,” Teva president and CEO Shlomo Yanai said in a statement. “This strategic partnership bolsters our biologics capabilities.”Teva, the world’s largest maker of generic drugs, already markets biosimilars in Europe, along with generic manufacturers Sandoz and Dr. Reddy’s, and pharmaceutical companies Merck & Co., Eli Lilly & Co. and AstraZeneca have recently announced the creation of biosimilars divisions.Financial terms of the deal between Lonza and Teva were not disclosed.
Lawmakers concerned international drug manufacturing presents risk of counterfeits
New York Concern has arisen about the manufacturing of ingredients for drugs in other countries, especially antibiotics like penicillin, according to published reports.
Drug manufacturing has mostly moved to countries such as India and China, but some lawmakers and analysts have said it increases the risks of counterfeits and bioterrorism.Already, more than 200 Americans have experienced dangerous drug reactions since November 2007 after taking counterfeit versions of the blood-thinning drug heparin manufactured in China containing a toxic chemical that merely mimics heparin. Last November, the Food and Drug Administration confiscated 11 lots of counterfeit heparin from a company based in Cincinnati.